Literature DB >> 26336408

Surgical treatment of late aortic prosthetic valve endocarditis: 19 years' experience.

Tuncer Eylem Yayla1, Adademir Taylan1, Tas Serpil1, Polat Ebru Bal2, Dönmez Arzu Antal1, Ak Adnan1, Akbulut Mustafa1, Serhat Bulbul1, Mehmet Aksut1, Tuncer Altug1.   

Abstract

AIM OF THE STUDY: We retrospectively analyzed the results of operations conducted for aortic prosthetic valve endocarditis in a single center over 19 years.
MATERIAL AND METHODS: From February 1992 to January 2011, we performed operations on 27 patients with aortic prosthetic valve endocarditis. Seventeen patients (63.0%) were male, and the mean age was 39.1 ± 14.2 (16-67) years. Blood cultures were positive in 11 patients (40.7%), and the most commonly identified microorganism was Streptococcus (7 patients, 25.9%). The mean duration of follow-up was 8.6 ± 4.7 years (0.5-18.2), adding up to a total of 136.9 patient/years.
RESULTS: Forty procedures were performed on these 27 patients. The most commonly performed procedure was aortic valve replacement with a prosthetic valve - 16 patients (59.3%). Fifteen patients were operated on during the active phase of infection. In-hospital mortality was observed in 11 patients (40.7%). Postoperatively, 12 patients (44.4%) had low cardiac output, 3 (11.1%) suffered from a heart block; none of them required permanent pacemaker implantation. The actuarial survival for 1 and 5 years was 55.6 ± 9.6% and 47.6 ± 9.7%, respectively.
CONCLUSIONS: Prosthetic valve endocarditis of the aortic valve is a challenging situation for the surgeon. The surgical treatment carries a high mortality rate and long-term survival is low. Among the survivors, however, recurrence and the need for reoperation are unlikely.

Entities:  

Keywords:  prosthetic valve endocarditis; surgery

Year:  2014        PMID: 26336408      PMCID: PMC4283851          DOI: 10.5114/kitp.2014.43837

Source DB:  PubMed          Journal:  Kardiochir Torakochirurgia Pol        ISSN: 1731-5530


Introduction

Prosthetic valve endocarditis (PVE) is a devastating complication of valve surgery. The treatment is usually prolonged medical therapy and surgery in complicated cases [1]. The incidence is reported to be highest in the early period [2]. We retrospectively analyzed the results of operations performed for late aortic PVE in a single center in 19 years.

Material and methods

The patient data were collected from the hospital records retrospectively. From February 1992 to January 2011, 27 consecutive patients with aortic prosthetic valve endocarditis underwent surgery at our institution. For the definitions of active, healed, prosthetic and culture negative endocarditis, modified Aranki criteria were used [3]. Endocarditis was labeled ‘active’ if the patient had fever and/or leukocytosis at the time of surgery or required surgical treatment before completion of a standard course of antibiotic treatment. Endocarditis was labeled ‘healed’ if surgery was performed after completion of antibiotic treatment and no signs of active infection (fever, leukocytosis) were present. Prosthetic valve endocarditis was defined as infection occurring on any type of tissue or mechanical valve device. Early endocarditis was defined as infective endocarditis that occurred within 60 days of valve replacement. Late prosthetic valve endocarditis was defined as infective endocarditis that occurred after 60 days of valve replacement. These were confirmed at operation by the presence of pannus formation, of vegetations, periprosthetic leakage or perivalvular tissue destruction. The presence of acute or chronic inflammatory changes at microscopy confirmed the diagnosis of endocarditis. The diagnosis of infective endocarditis was made according to the Duke criteria [4]. All patients were examined by transthoracic (TTE) or transesophageal (TEE) echocardiography. Echocardiography revealed valvular vegetation, regurgitation, or periprosthetic leakage. There were 17 male (63.0%) and 11 female (37.0%) patients with a mean age of 39.1 ± 14.2 (16-67) years. Of these PVE cases, 6 of them had double prosthetic valves. None of the PVE cases were early PVE. The mean duration between the valve replacement and the diagnosis of PVE was 20.0 ± 10.8 (range: 3-32) months. Vegetations on the mitral valve were detected in 3 cases (11.1%) and gross vegetations on aortic valves were detected in 6 patients (22.2%) preoperatively. Four patients (14.8%) had a history of 2 cardiac operations. The preoperative characteristics are summarized in Table I.
Tab. I

Preoperative characteristics

Preoperative characteristics n (%)
Fever12 (44.4%)
Septic emboli
 Central2 (7.4%)
 Peripheral3 (11.1%)
NYHA class
 Class I1 (3.7%)
 Class II5 (18.5%)
 Class III16 (59.3%)
 Class IV5 (18.5%)
Congestive heart failure22 (81.5%)
Renal dysfunction4 (14.8%)
 Infectious etiology3 (11.1%)
 Chronic dialysis dependent1 (3.7%)
Periprosthetic leakage13 (48.1%)
Emergency operation8 (29.6%)
LVD (EF < 40%)2 (7.4%)
ECG
 Sinus rhythm21 (77.8%)
 LBBB1 (3.7%)
 AF5 (18.5%)

NYHA – New York Heart Association, LVD – left ventricular dysfunction, ECG – electrocardiography, LBBB – left bundle branch block, AF – atrial fibrillation

Preoperative characteristics NYHA – New York Heart Association, LVD – left ventricular dysfunction, ECG – electrocardiography, LBBB – left bundle branch block, AFatrial fibrillation The blood cultures were positive in 11 patients (40.7%) and the identified microorganisms were Streptococcus in 7 cases (25.9%) and Staphylococcus in 4 patients (14.8%). Sixteen cases had negative cultures for both blood samples and the explanted surgical specimens.

Surgery

The patients were scheduled for an operation when the diagnoses were made. Fifteen patients (55.6%) underwent the operation in the active phase of the infection. In 12 cases (44.4%), the operation was performed after the antibiotic treatments were completed and the patient was stabilized. Mechanical prosthetic valves were preferred in most of the patients. All patients underwent moderate (28°C) hypothermic cardiopulmonary bypass by means of bicaval cannulation with cannulation of either the ascending aorta (23 patients) or the femoral artery (4 patients). The left ventricle was vented through the right superior pulmonary vein. Isothermic blood cardioplegic solution was administered via the retrograde route during aortic cross-clamping. For eradication of the PVE, radical debridement of all the necrotic and infected tissues was performed. Aortic root replacement and reconstruction were performed in 8 cases. The list of procedures is presented in Table II. The most commonly performed procedure was re-replacement of the aortic prosthesis with a mechanical valve. Primary repair of the periprosthetic leak was preferred in 2 mitral PVE and 4 aortic PVE cases. Only one of these cases had primary repair of both valves’ leak repaired primarily.
Tab. II

Procedures

Procedures n (%)*
Aortic valve replacement16 (59.3%)
 With mechanical prosthesis15 (55.6%)
 With bioprosthesis1 (3.7%)
Primary repair of periprosthetic leak at the aortic prosthesis4 (14.8%)
Aortic root replacement7 (25.9%)
 Bentall de Bono procedure3 (11.1%)
 Xenograft implantation3 (11.1%)
 Cabrol procedure1 (3.7%)
Aortic root enlargement1 (3.7%)
Fistula repair2 (7.4%)
Subaortic discrete membrane resection1 (3.7%)
Mitral valve procedures9 (33.3%)
 Mitral valve replacement6 (22.2%)
 Redo mitral valve replacement4 (14.8%)
 Primary repair of periprosthetic mitral valve leak2 (7.4%)
 Vegetectomy of mitral leaflets1 (3.7%)

Percentages are the ratio to the number of patients

Procedures Percentages are the ratio to the number of patients

Follow-up

All patients received at least four weeks of antibiotic therapy postoperatively. Broad-range antibiotics (vancomycin and aminoglycosides) were preferred for culture negative cases. The other patients were treated according to the antibiograms. The patients were involved in a follow-up program in the outpatient clinic of our hospital. The average duration of follow-up was 8.6 ± 4.7 years (0.5-18.2), adding up to a total of 136.9 patient/years.

Statistical analysis

The statistical analyses were performed with the SPSS 16.0 statistical software package. All continuous variables were expressed as mean ± standard deviation and the ranges were shown. All discrete variables were expressed as frequencies and percentages. Comparisons of the discrete variables were made by χ2 test. The survival, freedom from recurrence and freedom from reoperation analyses were performed with Kaplan Meier analysis.

Results

Mortality

Eleven patients (40.7%) had in-hospital mortality. Low cardiac output was the primary cause of mortality in all cases except one (patient 3). Six cases with in-hospital mortality underwent an emergency operation. The time and etiology of mortality are summarized in Table III.
Tab. III

Time and etiology of mortality

Initial procedure(s)Operation for PVEMortalityTime of mortalityEtiology
1AVR + MVRAVR + MVRIn-hospitalpo 0 dLCO
2AVRAVR + Aortic root enlargementIn-hospitalpo 0 dLCO
3AVR (1st procedure) Redo AVR + Aortic root enlargement + Aortic pseudoaneurysm repair (2nd procedure)Primary repair of periprosthetic leakIn-hospitalpo 12 dSepsis
4AVRCabrol procedureIn-hospitalpo 1 dLCO
5AVRXenograft replacement of aortic rootIn-hospitalpo 14 dLCO, sepsis
6AVRBentall de BonoIn-hospitalpo 3 dLCO
7AVR + MVRAVR + MVRIn-hospitalpo 27 dLCO, sepsis
8AVRMVRIn-hospitalpo 4 dLCO
9AVR + MVR + Aortic root enlargementAVRIn-hospitalpo 4 dLCO
10AVR (1st procedure) MVR (2nd procedure)AVR + MVRIn-hospitalpo 0 dLCO
11AVR + MVRAVR + MVRIn-hospitalpo 8 dLCO
12AVR + MVRPrimary repair of periprosthetic leak of the aortic and the mitral prosthesesAdpo 38 mExtracardiac
13AVRAVRAdpo 43 mExtracardiac
14AVR (1st procedure) Bentall de Bono (2nd procedure)Bentall de BonoAdpo 6 mRecurrent PVE

Ad – after discharge, AVR – aortic valve replacement, LCO – low cardiac output, MVR – mitral valve replacement, PVE – prosthetic valve endocarditis, po – postoperative, d – day, m – month

Time and etiology of mortality Ad – after discharge, AVR – aortic valve replacement, LCO – low cardiac output, MVR – mitral valve replacement, PVE – prosthetic valve endocarditis, po – postoperative, d – day, m – month

Morbidity

The total number of patients who had any morbidity was 18 (66.7%). Postoperative fever was seen in 11 patients (40.7%), five of whom did not have fever preoperatively. Twelve patients (44.4%) had low cardiac output and only two of them survived. Complete heart block was present in 1 (11.1%) patients postoperatively and none of them required permanent pacemaker implantation. Two of the patients with postoperative heart block had in-hospital mortality due to low cardiac output (5 cases). Renal dysfunction was present in 12 (44.4%) patients and 4 (14.8%) required dialysis. Pulmonary morbidity was present in 4 (14.8%) patients. Cerebrovascular events occurred in 3 (11.1%) patients. One of them had septic central emboli preoperatively and she died due to low cardiac output during hospitalization and another patient died in his 43rd month due to chronic renal failure. Of the surviving 16 patients, follow-up was complete in all cases. Three patients (11.1%) had mortality after discharge. The time and etiology of mortality are summarized in Table III. Three patients had recurrences (11.1%) postoperatively and only one of them was operated in the active phase of infection. The actuarial survival for 1, and 5 years was 55.6 ± 9.6% and 47.6 ± 9.7%, respectively (Fig. 1).
Fig. 1

Cumulative survival

Cumulative survival Recurrence of infection occurred in 3 (11.1%) cases and 2 patients (5.6%) had reoperations. The blood cultures were negative in one of the patients who had recurrences. The other two patients had positive cultures for Streptococcus and Staphylococcus, respectively. The survival rate free from recurrence from infection at 1 year was 86.8 ± 7.3% and remained stable throughout the follow-up period (Fig. 2). The survival rate free from reoperation at 1 year was 92.6 ± 5.0% and remained stable throughout the follow-up period (Fig. 3).
Fig. 2

Survival rate free from recurrence

Fig. 3

Survival rate free from reoperation

Survival rate free from recurrence Survival rate free from reoperation

Discussion

The incidence of PVE is reported to be 0.32 to 1.2% per patient year with a cumulative incidence of 5% in 10 years [5]. This study is important as it is focused mainly on the surgical treatment of the late aortic PVE. There was a high mortality rate with a high rate of re-replacement with a mechanical prosthesis. The majority of the patient group had congestive heart failure. So, the outcomes of this study must be carefully analyzed. Fariñas et al. reported that preoperative NYHA functional class II or IV, alcohol consumption, and previous endocarditis were significantly associated with increased PVE risk. Among the perioperative factors, they found that postoperative fever in the ICU and gastrointestinal bleeding are associated with increased PVE risk [6]. An interesting study by Shapira et al. reported unexpected histopathological findings of inflammation in patients operated for noninfectious etiology with an incidence of 0.9% and about a quarter of them required redo surgery for PVE [7]. Common clinical presentations of PVE are persistent fever, profound anorexia, new onset murmur, heart block, congestive heart failure (CHF), and embolic events. In our patient group, 44% of them presented with fever, about 20% with septic emboli and more than 80% presented with congestive heart failure. Lytle et al. reported less than ¼ of our incidence in their series [8]. Septic embolus was reported to be a risk factor for mortality for worsening the cerebral edema or conversion of an ischemic stroke into a hemorrhagic case [9]. Of the 5 septic emboli patients, 2 of them had cerebral emboli and they both had in-hospital mortality. Early PVE frequently involves the junction of the sewing ring and annulus, leading to valve dehiscence and paravalvular abscesses and carries worse prognosis than late PVE [5]. The incidence of annular abscess was reported to be around 15% in a previous study by Lytle and colleagues [8] but up to 63% incidence was also reported [5]. In our patient cohort, almost 50% of the patients had annular involvement. A significant drawback of our study is the high rate of culture negative results. This fact is mostly related to the blood sampling for cultures during the antibiotic therapy. This has been stated as an important factor in the negative results [5]. We have continued the antibiotic therapy for 6 weeks in these cases especially, as did Hyde and colleagues [10]. Another factor affecting the negative results of the cultures may be the patient group. Lytle and colleagues reported much higher incidence of negative cultures in the late PVE patients [8]. The surgical treatment for PVE carries high mortality risk. Mortality rates ranging from 20% to 80% have been reported [8, 11, 12]. Musci and colleagues report that PVE is a challenging situation with high early and late mortality [13]. In a population of more than 300 PVE patients, their early mortality rates were about 30%. The long-term survivals were also not so satisfactory. The significant predictors for mortality were mechanical support, emergency operation, and preoperative high doses of inotropes, mitral valve replacement and age at the operation [13]. It can be seen that 75% of the emergency operations in this report had in-hospital mortality. Edwards and colleagues reported that age, infection of the explanted prosthesis, and size of the prosthesis had a significant effect on the early mortality [14]. Recurrence and need for reoperation for PVE is another important and life-threatening feature of PVE. In our study, 3 patients (11.1%) had recurrences. Two of them had early recurrences of PVE which presented with an early periprosthetic leak requiring reoperation and the patients died after the reoperations. Primary repair of a periprosthetic leak could be a matter of debate for recurrence. However, among the 6 primary repair procedures (4 aortic and 2 mitral), only one patient had recurrence and reoperation, presented in Table III as patient 3. The size of the patient group is too small to make significant conclusions about this matter. The other case occurred 6 months later and the patient has also died of heart failure. Excluding these cases, the recurrences and reoperation requirements were steady throughout the follow-up duration (Fig. 2 and Fig. 3). Fedoruk et al. reported that intravenous drug abuse and human immunodeficiency virus were predictors for recurrence and reoperations for PVE [15]. The high rate of reoperation-free survival in our patients is compatible with other series [14]. There is a high incidence of postoperative complications in our series. Such results have also been reported by a recent report of PVE from China [1]. Considering the high rate of preoperative congestive heart failure, these two factors may interact to increase the perioperative mortality in this patient group. Another point of debate may be the use of a mechanical prosthesis commonly in a PVE patient group. Although bioprosthetic materials are preferred in such operations [5], mechanical prostheses are reported to have higher long-term survival in a UK registry [14]. We used silver-coated Silzone mechanical valves in operations for infective endocarditis. The rates of periprosthetic leakage were a question of debate at the time and the effect of those valves on the periprosthetic leakage has been reported before [16]. Apart from such a clinical scenario, we did not have significant problems with mechanical valves. The low rate of recurrence and reoperation-free survival also confirm this result.

Conclusions

Prosthetic valve endocarditis of the aortic valve is a challenging situation for the surgeon. A significant proportion of the patients have important comorbidities and significant valvular destruction and invasion. Emergency operations have high mortality. The surgical treatment carries a high mortality rate and the long-term survival is not so different. Among the survivors, however, recurrence and need for reoperation are unlikely.
  15 in total

1.  Risk factors of prosthetic valve endocarditis: a case-control study.

Authors:  M Carmen Fariñas; Alberto Pérez-Vázquez; Concepción Fariñas-Alvarez; J Daniel García-Palomo; José M Bernal; José M Revuelta; Jesús González-Macías
Journal:  Ann Thorac Surg       Date:  2006-04       Impact factor: 4.330

2.  Surgical treatment for active infective prosthetic valve endocarditis: 22-year single-centre experience.

Authors:  Michele Musci; Michael Hübler; Aref Amiri; Julia Stein; Susanne Kosky; Rudolf Meyer; Yuguo Weng; Roland Hetzer
Journal:  Eur J Cardiothorac Surg       Date:  2010-05-23       Impact factor: 4.191

3.  Early onset prosthetic valve endocarditis: the Cleveland Clinic experience 1992-1997.

Authors:  S M Gordon; J M Serkey; D L Longworth; B W Lytle; D M Cosgrove
Journal:  Ann Thorac Surg       Date:  2000-05       Impact factor: 4.330

Review 4.  Prosthetic valve endocarditis.

Authors:  Balakrishnan Mahesh; Gianni Angelini; Massimo Caputo; Xu Yu Jin; Alan Bryan
Journal:  Ann Thorac Surg       Date:  2005-09       Impact factor: 4.330

5.  Prosthetic valve endocarditis in a multicenter registry of Chinese patients.

Authors:  Hee-Hwa Ho; Chung-Wah Siu; Kai-Hang Yiu; Hung-Fat Tse; Wing-Hung Chui; Wing-Hing Chow
Journal:  Asian Cardiovasc Thorac Ann       Date:  2010-10

Review 6.  Latent infective endocarditis: epidemiology and clinical characteristics of patients with unsuspected endocarditis detected after elective valve replacement.

Authors:  Nadiv Shapira; Ofer Merin; Eliezer Rosenmann; Ilia Dzigivker; Dan Bitran; Amos M Yinnon; Shuli Silberman
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

7.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.

Authors:  D T Durack; A S Lukes; D K Bright
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

8.  Surgical treatment of prosthetic valve endocarditis.

Authors:  B W Lytle; B P Priest; P C Taylor; F D Loop; S K Sapp; R W Stewart; P M McCarthy; D Muehrcke; D M Cosgrove
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

9.  Aortic valve endocarditis. Determinants of early survival and late morbidity.

Authors:  S F Aranki; F Santini; D H Adams; R J Rizzo; G S Couper; N M Kinchla; J S Gildea; J J Collins; L H Cohn
Journal:  Circulation       Date:  1994-11       Impact factor: 29.690

10.  Brain damage after open heart surgery in patients with acute cardioembolic stroke.

Authors:  M Maruyama; Y Kuriyama; T Sawada; T Yamaguchi; T Fujita; T Omae
Journal:  Stroke       Date:  1989-10       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.